Health

SHERIDAN, WYOMING – August 10, 2025 – The GSMA is preparing to host one of the most significant technology gatherings of the decade as MWC Barcelona returns March 2–5, 2026, celebrating 20 years of convening global connectivity leaders. The milestone event aims to blend two decades of innovation with a forward-looking agenda focused on AI, 5G, enterprise technology, and policy shaping for the next generation of connected solutions.

Two Decades of Industry Collaboration and Impact

SHERIDAN, WYOMING – August 10, 2025 – Eli Lilly is navigating a three-pronged challenge on drug pricing, from regulatory proposals to competitive market dynamics, even as it advances its next-generation oral weight loss candidate, orforglipron. On its second quarter earnings call, the company’s leadership underscored that pricing strategy will remain central to sustaining market share and delivering shareholder value.

Balancing Innovation and Pricing in Obesity Therapeutics

SHERIDAN, WYOMING – August 10, 2025 – Globus Medical, Inc. (NYSE: GMED) reported strong second-quarter 2025 results, achieving record non-GAAP earnings per share and double-digit revenue growth, driven by its U.S. Spine business and strategic integration of Nevro. The performance underscores the company’s operational discipline and its continued push to expand robotic-assisted surgery adoption.

Double-Digit Revenue Growth Across Core Segments

SHERIDAN, WYOMING – August 10, 2025 – Gilead Sciences is signaling strong confidence in its HIV prevention portfolio, including the twice-yearly injectable PrEP therapy Yeztugo, despite growing uncertainty over the future of the U.S. Preventive Services Task Force (USPSTF). The federally recognized panel’s recommendations currently mandate insurance coverage for preventive services, but a postponed meeting has fueled speculation that Health Secretary RFK Jr. could overhaul or dismantle the group.

SHERIDAN, WYOMING – August 10, 2025 – In a rapid reversal, Dr. Vinay Prasad has resumed leadership of the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) less than two weeks after stepping down. The reinstatement, confirmed by the Department of Health and Human Services (HHS), ends speculation over the agency’s direction during a critical period for advanced biologics oversight.

FDA Leadership Transition Reverses Course

SHERIDAN, WYOMING – August 9, 2025 – The cell and gene therapy (CGT) sector stands at a pivotal moment. Once buoyed by multibillion-dollar valuations, companies like Sarepta Therapeutics and bluebird bio have faced sharp declines, underscoring the sector’s commercial growing pains. Industry leaders now agree: sustainable success will depend on advancing manufacturing, aligning global regulations, and better communicating value to payers.

Next-Generation Manufacturing as a Growth Engine

SHERIDAN, WYOMING – August 8, 2025 – Major pharmaceutical companies are doubling down on venture funds and incubator programs to identify cutting-edge science, foster strategic partnerships, and position themselves in emerging therapeutic and geographic markets. While mergers and acquisitions remain a dominant growth driver, these initiatives provide a long-term “farm system” for high-value pipeline assets.

SHERIDAN, WYOMING – August 8, 2025 – A wave of high-value licensing deals between multinational pharmaceutical companies and Chinese biotechs is reshaping the global drug development landscape. While the headlines highlight billion-dollar transactions, the reality on the ground is a complex mix of opportunity and survival for China’s crowded biotech sector.

SHERIDAN, WYOMING – August 8, 2025 – In a move aimed at reducing the nation’s dependence on overseas pharmaceutical production, the U.S. Food and Drug Administration (FDA) has launched PreCheck, a two-phase program designed to speed regulatory review and strengthen domestic drug manufacturing capacity.

SHERIDAN, WYOMING – July 29, 2025 – Roche is accelerating its multi-modal approach to Alzheimer’s disease, unveiling new data at the Alzheimer’s Association International Conference (AAIC) that spotlight the therapeutic potential of trontinemab and the diagnostic promise of its Elecsys® pTau217 blood test. Together, these innovations signal a possible shift toward earlier, more accessible, and more precise detection and treatment of the world’s most prevalent neurodegenerative disease.

Trontinemab shows rapid amyloid clearance with low ARIA risk